Management Team

Chairman
Simon Wu

Education BS in Chemical Engineering, Tunghai University, Taiwan
Current Position:
1. Chairman, San Fu Chemical Co., Ltd., Taiwan
2. Chairman, Li Fu Carbon Dioxide Co., Ltd., Taiwan
3. Directors of the Boards, International Nitto Technology Co., Ltd.; Hongchen Enterprise Co., Ltd.; San Fu Global Co., Ltd.
Experience:
1. President & Vice Chairman, Air Products San Fu Co., Ltd.
2. Manager & Director, Formosa Chemicals & Fibre Crop.
3. Chairman, Industrial Gas Association of Taiwan.
President
Daniel C.H. Cheng

Education PhD in Chemical Engineering, University of Michigan, USA MS in Chemical Engineering, Oklahoma State University, USA BS in Chemical Engineering, Tunghai University, Taiwan
Experience:
1. President, PhytoHealth Corp.
2. VP, Development Center for Biotechnology (DCB), Taiwan.
3. General Director, Biotechnology & Pharmaceutical Industries Promotion Office (BPIPO), MOEA, Taiwan
4. Science & Technology Advisor, Department of Industrial Technology, MOEA, Taiwan
5. Founder, Chairman & President, Caleb Pharmaceuticals, Inc., Taiwan
6. Senior Researcher & Manager, Laboratory of Controlled Release Technology, Union Chemical Laboratory, ITRI, Taiwan
7. Adjunct Professor, Department of Chemical Engineering, Tunghai Univ., Taiwan
8. Manager of R&D, Theratech, Inc. Salt Lake City, Utah, USA
Vice President & Director of Clinical Operations
David Yeh

Education MS in Life Sciences, National Tsing-Hua University, Taiwan BS in Chemical Engineering, Tunghai University, Taiwan
Experience:
1. Vice President, PhytoHealth Corp.
2. COO, Bestat PharmaServices Corp.
3. Senior Director, Clinical Operations, Oneness Biotech Co., Ltd.
4. CEO, Protech PharmaServices Corp.
5. CEO, A+ Inc.
6. Senior Director, Clinical Operations, Microbio Co., Ltd.
7. Director, APEX International Co., Ltd. (Currently Parexel)

SFB101

First-in-Class novel drug in preclinical stage

What is a retinal disease?

The retina consists of millions of photoreceptor cells and other nerve cells responsible for receiving and organizing visual signals.¹ Population-based studies show retinal diseases prevalence ranging from 5.35% to 21.02% in individuals aged 40 and above.² Retinal diseases are the primary cause of irreversible blindness in developed countries and the second leading cause of blindness in developing countries, following cataracts.

Unmet Medical Needs

Anti-VEGF therapy reduces vision loss in wet macular degeneration and diabetic retinopathy. However, frequent intravitreal injections increase infection risk and burdens. Urgently needed are effective, patient-friendly drugs to prevent irreversible blindness.

Preclinical Stage

We are co-developing SFB101 with a national research institute in Taiwan, currently in the preclinical stage.

A novel drug candidate potential effective and patient-friendly treat the retinal diseases, preventing blindness.

Richard H. Masland. Neuron. 2012; 76(2): 266-280.
Matthew J Burton et al. Lancet Glob Health. 2021; 9(4): e489-e551.

SFB201

A First-in-class liposomal drug that effectively regulates the immune system's balance for prophylaxis against acute Graft-versus-Host Disease (aGvHD).

What is GvHD?

Many blood disorders, such as leukemia, require allogeneic hematopoietic stem cell transplantation (AHSCT) as a vital treatment option. However, graft-versus-host disease (GvHD), where immune cells from the donor attack the recipient's organs, remains a major and potentially fatal complication of AHSCT¹.

The action of balancing the immune system.

SFB201 (originally named RGI-2001) is a new chemical entity (NCE) with liposomal formulation. The primary mechanism involves inducing an increase in regulatory T cells (Treg), initiating specific immune tolerance. These antigen-specific Tregs have been shown to downregulate the immune response directed toward specific antigens without causing generalized immunosuppression².

Plan to enter Phase 3 clinical trial in 2024

The Phase 1/2a trial (NCT01379209)³ and the Phase 2b trial (NCT04014790)⁴in the USA has been completed. Planning to initiate a multi-center, multi-national Phase 3 clinical trial in the USA, Taiwan, and most likely, South Korea, in 2024.

三福生技